Ticker brief
EYPT
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
57
authors 14d
25
crowd 14d
-2.1σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-08-15 → 2026-08-28 · now -0.50 (−1 bearish … +1 bullish)
Who spoke25
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @semodough | C | -3.01 | 10 | -0.22 |
| @adamfeuerstein | A | +1.41 | 8 | -0.49 |
| @BiopharmIQ | B | · | 4 | -0.33 |
| @PersimmonTI | A | -0.57 | 3 | -0.20 |
| @OpenOutcrier | C | · | 3 | -0.53 |
| @cfaryanoconnell | C | -1.48 | 3 | +0.00 |
| @ClassicRoy | C | -1.52 | 3 | +0.00 |
| @Briefingcom | B | +0.50 | 2 | -0.67 |
| @OptionRunners | C | +1.20 | 2 | -0.52 |
| @OracleNYSE | C | -0.08 | 2 | +0.22 |
| @Analytica_X | B | +1.03 | 2 | +0.15 |
| @BiotechCH | B | -0.38 | 2 | -0.50 |
| @wallstengine | B | -1.90 | 1 | -0.50 |
| @BioStocks | C | -3.02 | 1 | +0.15 |
| @jbulltard1 | C | +0.26 | 1 | -0.70 |
| @optionscjp | C | -1.28 | 1 | -0.60 |
| @theflynews | C | · | 1 | -0.55 |
| @TWFeditor | C | +0.53 | 1 | -0.80 |
| @IBDinvestors | B | +1.05 | 1 | -0.65 |
| @PrismMarketView | C | · | 1 | -0.60 |
| @PrismDM | A | -2.10 | 1 | -0.60 |
| @fwpharma | B | +0.98 | 1 | -0.60 |
| @FiercePharma | B | -1.09 | 1 | -0.70 |
| @TheNewMoney_app | C | · | 1 | -0.30 |
| @fundmyfund | B | -1.58 | 1 | -0.50 |
Recent signals30of 57 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @BiotechCH | -0.50 | EYPT's wet-AMD therapy missed its Phase 3 primary endpoint despite favorable secondary signals. | · | tweet ↗ |
| 2026-08-28 | @BiotechCH | -0.50 | Biotech show agenda summarizes several material trial, financing and approval events. | · | tweet ↗ |
| 2026-08-25 | @ClassicRoy | +0.00 | Reports increasing unusual options volume across the listed names. | · | tweet ↗ |
| 2026-08-25 | @cfaryanoconnell | +0.00 | Lists assets experiencing increasing unusual options volume | · | tweet ↗ |
| 2026-08-24 | @ClassicRoy | +0.00 | Reports increasing unusual options volume without specifying directional call or put flow. | · | tweet ↗ |
| 2026-08-21 | @BiopharmIQ | -0.70 | Summarizes the week's largest biotech movers and their associated catalysts. | · | tweet ↗ |
| 2026-08-21 | @semodough | +0.10 | Suggests retinal-specialist enthusiasm and trust in AXPAXLI may be increasing. | · | tweet ↗ |
| 2026-08-21 | @semodough | +0.00 | Recommends an OCUL Piper webcast after EYPT data but provides little standalone thesis. | · | tweet ↗ |
| 2026-08-19 | @semodough | +0.00 | Cowen analysis argues OCUL's SOL-R screening design reduces variability and derisks non-inferiority. | · | tweet ↗ |
| 2026-08-19 | @semodough | +0.00 | Announces a Mizuho expert call on EYPT trial data and Phase 3 implications. | · | tweet ↗ |
| 2026-08-19 | @fundmyfund | -0.50 | Lists the worst weekly performers and expects WYFI to open still lower after a convertible financing. | · | tweet ↗ |
| 2026-08-18 | @TheNewMoney_app | -0.30 | Reports a large purchase of EYPT puts with strike, premium and expiry. | · | tweet ↗ |
| 2026-08-18 | @cfaryanoconnell | +0.00 | Reports increasing unusual option volume without specifying call or put direction. | · | tweet ↗ |
| 2026-08-18 | @FiercePharma | -0.70 | EyePoint shares plunge after Duravyu stumbled in a phase 3 trial. | · | tweet ↗ |
| 2026-08-18 | @Analytica_X | +0.10 | Summarizes extraordinary volume around company developments while warning about higher financing hurdles. | · | tweet ↗ |
| 2026-08-18 | @Analytica_X | +0.20 | Reports unusually high trading volumes and associated catalysts for four small-cap stocks. | · | tweet ↗ |
| 2026-08-17 | @semodough | -0.40 | Baird doubts Duravyu's approvability, increasing the likelihood OCUL's Axpaxli becomes the only TKI insert. | · | tweet ↗ |
| 2026-08-17 | @fwpharma | -0.60 | EyePoint's six-month implant failed to perform in its first pivotal wet-AMD trial. | · | tweet ↗ |
| 2026-08-17 | @OpenOutcrier | -0.40 | Recaps negative third-party comments across several stocks. | · | tweet ↗ |
| 2026-08-17 | @semodough | -0.60 | Claims OCUL's AXPAXLI is far more potent and uses a much smaller needle than EYPT's product | · | tweet ↗ |
| 2026-08-17 | @adamfeuerstein | -0.60 | Reports disappointing EYPT study results and implies competitive benefit for OCUL. | · | tweet ↗ |
| 2026-08-17 | @OptionRunners | -0.40 | Reports closure of 10,000 October $10 puts for $5.60. | · | tweet ↗ |
| 2026-08-17 | @OracleNYSE | +0.00 | Notes unspecified speculation circulating after a trial. | · | tweet ↗ |
| 2026-08-17 | @PersimmonTI | +0.50 | Reports unconfirmed takeover chatter that Amgen is considering EyePoint. | · | tweet ↗ |
| 2026-08-17 | @ClassicRoy | +0.00 | Lists the first six names showing increasing unusual options volume. | · | tweet ↗ |
| 2026-08-17 | @cfaryanoconnell | +0.00 | Lists securities with increasing unusual options volume without specifying call or put direction. | · | tweet ↗ |
| 2026-08-17 | @BiopharmIQ | -0.60 | Biotech news list reports FDA acceptance, positive trials, a merger, placement and severe data-related move. | · | tweet ↗ |
| 2026-08-17 | @adamfeuerstein | -0.50 | Reacting 'Yikes' rejects Jefferies' defense of EYPT; MLTX is only the analyst's comparison. | · | tweet ↗ |
| 2026-08-17 | @OracleNYSE | +0.45 | Relays Barron's view that the EYPT selloff may be an overreaction. | · | tweet ↗ |
| 2026-08-17 | @PrismDM | -0.60 | Reports EYPT's pivotal trial miss and the resulting positive read-through and price move for OCUL. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.